Clinical Specialist Rheumatology or Lung


<















If you want to hit RA bonus big time this year just talk to your local Janssen Remicade rep. They just took a 33% cut in bonus (the second in 12 months) while exceeding target. Word is they are rolling over to let the business go since JnJ just announced the "old Centacor group" would not be transitioned after Remicade losses patent protection. Stick your hands out, its time to take it deep. My prediction is 40% market share by end of 2015 if not sooner and single handedly taking 90% of the infusion market.